CryoPort, Inc. Common Stock
CYRXCryoPort, Inc. (CYRX) specializes in temperature-controlled supply chain solutions for the transportation and storage of biotech and pharmaceutical products. The company provides cryogenic shipping services using its proprietary CryoPort Express platform, ensuring the safe and reliable movement of sensitive biologics, vaccines, and cell therapies worldwide.
Company News
Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised ...
The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene ...
The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024)...
Cryoport announced the launch of the MVE Fusion® 800 Series, a self-sustaining cryogenic freezer that eliminates the need for continuous liquid nitrogen supply. The compact system, recognized with the ISBER Outstanding New Product Award, is designed for space-constrained environments like medical research facilities, hospitals, and biorepositori...
Cryoport Systems has become the first global supply chain solutions company to achieve ISO 21973 certification, demonstrating its leadership in ensuring safe and traceable transportation of cell and gene therapies.
